Public Company Healthcare

Bayer

Leverkusen, North Rhine-Westphalia, Germany

Global life sciences company with core competencies in healthcare and agriculture (nutrition/crop science).

Focus Areas
Pharmaceuticals, Biopharmaceuticals, Women’s health
Website
www.bayer.com

Tracked deals

3

3 tracked deals across 2020-2026.

Recent pace

1

1 tracked deal announced in the last 12 months.

Deal mix

Buyout

3 buyout

Bayer Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Bayer. 2 2020 ~1 est. 1 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Bayer to Acquire Perfuse Therapeutics
    May 7, 2026
    Buyer
    Bayer
    Target
    Perfuse Therapeutics
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Bayer announced an agreement to acquire Perfuse Therapeutics for up to $2.45 billion, including a $300 million upfront payment plus development, regulatory, and commercial milestone payments. The deal is intended to strengthen Bayer’s ophthalmology pipeline by adding PER-001, an investigational therapy in Phase II for glaucoma and diabetic retinopathy.

  • Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)
    October 26, 2020
    Buyer
    Bayer AG
    Target
    Asklepios BioPharmaceutical, Inc. (AskBio)
    Seller
    TPG Capital, Vida Ventures
    Industry
    Biotechnology
    Location
    North Carolina, United States
    Type
    Buyout

    Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.

  • Bayer Acquires UK Biotech KaNDy Therapeutics Ltd.
    August 11, 2020
    Buyer
    Bayer
    Target
    KaNDy Therapeutics Ltd.
    Industry
    Biotechnology
    Location
    Hertfordshire, United Kingdom
    Type
    Buyout

    Bayer has agreed to acquire UK-based clinical-stage biotech KaNDy Therapeutics Ltd. for an upfront $425 million with up to $450 million in additional milestone payments, expanding Bayer's women's healthcare drug development pipeline—specifically the investigational non-hormonal compound NT-814 for menopausal vasomotor symptoms. The acquisition, subject to customary conditions, was announced in August 2020 and is expected to close in September 2020.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 3 tracked deals by Bayer. Acquisitions in North Carolina 1 tracked deal by Bayer.

Related articles

Selling a company? Get in front of buyers like Bayer

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →